METOCLOPRAMIDE IN TARDIVE DYSKINESIA

The effect of single intravenous doses of metoclopramide (10 mg, 20 mg and 40 mg) have been compared with placebo (saline) in a double blind randomised study in 10 patients with tardive dyskinesia following long term neuroleptic therapy. Tardive dyskinesia rating scores were decreased significantly...

Descripción completa

Detalles Bibliográficos
Autores principales: Hemanani, T.J., Dashputra, P.G., Sarda, R.N.
Formato: Texto
Lenguaje:English
Publicado: Medknow Publications 1983
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3012337/
https://www.ncbi.nlm.nih.gov/pubmed/21847271
Descripción
Sumario:The effect of single intravenous doses of metoclopramide (10 mg, 20 mg and 40 mg) have been compared with placebo (saline) in a double blind randomised study in 10 patients with tardive dyskinesia following long term neuroleptic therapy. Tardive dyskinesia rating scores were decreased significantly (P<0.01) 6 hours after administration of metoclopramide 20 mg and 40 mg when compared with placebo. Reduction of tardive dyskinesia by metoclopramide-a D(2)receptor blocking agent suggest that D(2)receptors may be involved in the mediation of this syndrome.

Ejemplares similares